Prognostic nutritional index predicts outcomes in hepatocellular carcinoma treated with atezolizumab and bevacizumab
2026-01-27
(Press-News.org) Background and Aims
The prognostic nutritional index (PNI), calculated from serum albumin and lymphocyte count, reflects a patient’s immune-nutritional status and has been proposed as a prognostic marker in hepatocellular carcinoma (HCC). However, its role in advanced HCC patients treated with atezolizumab plus bevacizumab (Ate/Bev) remains unclear. In this study, we aimed to evaluate the prognostic value of PNI in patients receiving first-line Ate/Bev therapy.
Methods
We retrospectively analyzed 362 patients with unresectable HCC who received Ate/Bev between November 2020 and June 2023 across two centers. Based on prior literature, a cutoff of 45 was used to classify patients into low-PNI (<45) and high-PNI (≥45) groups. Propensity score matching was performed to balance baseline characteristics.
Results
After propensity score matching, 130 patients (65 per group) were included in the analysis. The high-PNI group showed a significantly lower incidence of grade ≥ 3 treatment-related adverse events (10.8% vs. 24.6%, p = 0.039), a higher objective response rate (38.4% vs. 20.0%, p = 0.037), and significantly longer overall survival (16.7 vs. 7.9 months, p = 0.009). Although progression-free survival was longer in the high-PNI group (4.8 vs. 3.0 months), the difference was not statistically significant (p = 0.597). Multivariate analysis confirmed that PNI was an independent predictor of overall survival (hazard ratio: 0.574, 95% confidence interval: 0.353–0.933, p = 0.025), after adjusting for vascular invasion, alpha-fetoprotein levels, concurrent therapy, and post-treatment interventions.
Conclusions
PNI is an independent prognostic factor for overall survival in advanced HCC patients treated with Ate/Bev in real-world clinical practice. Incorporating PNI into routine assessments may enhance risk stratification and guide therapeutic decision-making.
Full text
https://www.xiahepublishing.com/2310-8819/JCTH-2025-00418
The study was recently published in the Journal of Clinical and Translational Hepatology.
The Journal of Clinical and Translational Hepatology (JCTH) is owned by the Second Affiliated Hospital of Chongqing Medical University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health sciences of liver diseases. JCTH has established high standards for publication of original research, which are characterized by a study’s novelty, quality, and ethical conduct in the scientific process as well as in the communication of the research findings. Each issue includes articles by leading authorities on topics in hepatology that are germane to the most current challenges in the field. Special features include reports on the latest advances in drug development and technology that are relevant to liver diseases. Regular features of JCTH also include editorials, correspondences and invited commentaries on rapidly progressing areas in hepatology. All articles published by JCTH, both solicited and unsolicited, must pass our rigorous peer review process.
Follow us on X: @xiahepublishing
Follow us on LinkedIn: Xia & He Publishing Inc.
END
ELSE PRESS RELEASES FROM THIS DATE:
2026-01-27
PULLMAN, Wash. — A new tool developed by Washington State University researchers could someday provide daily or weekly forecasts of water availability in the mountains similar to a weather forecast that agencies could use for important water management decisions.
The researchers recently presented their forecast tool for snow-water equivalent, which predicts potential water availability, at the Association for the Advancement of Artificial Intelligence Conference on Artificial Intelligence in ...
2026-01-27
Training the Next Generation of Translational Virologists: Reflections from the 2025 Global Virus Network Short Course
Tampa, FL, USA – January 27, 2026 – The Global Virus Network’s (GVN) 2025 Short Course in Translational Virology brought together a remarkable international cohort in December 2025 for eight days of scientific immersion, mentorship, and hands-on learning at the intersection of virology, medicine, and global health. Representing more than 90 Centers of Excellence and Affiliates across 40+ countries, GVN brings together leading human and animal virologists to advance research collaboration ...
2026-01-27
Last year, when The New York Times reported that Amazon’s robotics team’s ultimate goal was to automate 75% of the company’s operations, replacing more than half a million human jobs in an attempt to pass cost savings onto customers, it was a stark reminder of robots’ ever-expanding role in reshaping the American workplace.
Meanwhile, at Hyundai’s auto plant in Georgia, more than 1,000 robots work alongside almost 1,500 human employees.
But as ...
2026-01-27
The paper “Prioritizing Sustainable Development of Ecologically Sensitive Regions” was published recently in Ecosystem Health and Sustainability – A Science Partner Journal. The innovative research calls for merging AI with indigenous knowledge and targeting “tipping point” ecosystems to achieve the Sustainable Development Goals.
A groundbreaking new study urges a global priority shift toward sustainable development in four types of ecologically sensitive regions, warning they are at imminent risk of catastrophic “tipping points” due to climate change and human pressure. The research, ...
2026-01-27
The risks of climate change to human wellbeing are serious. Appropriate mitigation and adaptation require structural changes that are only likely to occur as a result of collective climate action. Danielle Goldwert, Madalina Vlasceanu, and colleagues explored what causes people to take collective climate action in a megastudy capable of directly comparing 17 behavioral interventions. The 17 interventions were derived from an open call to behavioral scientists and advocacy experts and included various ...
2026-01-27
BOSTON, Mass. and PORTLAND, Maine, January 27, 2026// Boston University (BU) today announced it has been awarded a $2 million research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The funding will support a clinical study evaluating motor and cognitive factors associated with changes in walking for people with Parkinson’s disease who use MedRhythms’ MOVIVE (MR-005), a safe, use-at-home medical device that delivers rhythmic auditory stimulation (RAS) to support gait rehabilitation and motor function.
This study was funded through The Michael ...
2026-01-27
The advisor-advisee relationship is central to most doctoral education models. Yet not all students trust their advisors. Danfei Hu, Jonathan E. Cook, and colleagues sought to examine the importance of this relationship to success and wellbeing in graduate school. The authors focused on the first year of graduate school, a time in which PhD students adapt to their role as scholars and in which large numbers of students drop out. In a prospective longitudinal study of 558 incoming PhD students, primarily in STEM fields, at three US research universities, the authors found that PhD ...
2026-01-27
Engineering can create weapons systems or systems for defense and wellbeing. But can engineering create peace? In a Perspective, Guru Madhavan and colleagues propose an expansive mode of engineering practice that seeks to reduce conflict. In a world where the technical choices about pumping stations for transboundary water conveyance projects can become tense diplomatic questions, engineering for peace requires the competence to build systems that work as intended, the capability to foresee how such systems might be used or misused, ...
2026-01-27
Jan 27, 2026 -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico’s proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.
According to the agreement, Insilico Medicine will utilize its proprietary Pharma.AI platform to focus on the design and optimization ...
2026-01-27
Across the physical world, many intricate structures form via symmetry breaking. When a system with inherent symmetry transitions into an ordered state, it can form stable imperfections known as topological defects. Such defects are found everywhere, from the large-scale structure of the universe to everyday materials, making them a powerful way to study how order emerges in complex systems.
We have a tool to study these defects: nematic liquid crystals. In these materials, molecules can rotate freely while remaining roughly aligned, providing a clear and controllable ...
LAST 30 PRESS RELEASES:
[Press-News.org] Prognostic nutritional index predicts outcomes in hepatocellular carcinoma treated with atezolizumab and bevacizumab
